Coeptis Therapeutics Holdings, Inc. Material Event - What Happened

Investors tracking Coeptis Therapeutics should be aware of a significant development impacting the company's corporate governance and investor confidence. This summary details a recent event that touches on fundamental aspects of its Nasdaq listing.

---

Event Description

Coeptis Therapeutics recently received a warning letter from Nasdaq, the stock exchange where its shares trade. Nasdaq informed Coeptis that it is non-compliant with listing rules because the company failed to hold its annual shareholder meeting within the required timeframe. This serves as a critical warning, demanding immediate attention and resolution.

Companies listed on major stock exchanges like Nasdaq must follow specific rules to remain listed. A fundamental rule requires them to hold an annual meeting for shareholders within a certain period, typically within 12 months of their fiscal year-end. Coeptis's fiscal year ended on December 31, 2024, and the company did not hold that meeting by the deadline. While the 8-K filing does not specify why the meeting was missed, such delays can result from administrative oversights, internal governance challenges, or a lack of focus on compliance. This issue concerns basic corporate governance, transparency, and keeping shareholders informed and engaged, rather than fundraising or share sales.

Event Date/Timeline

Coeptis received this warning letter from Nasdaq on January 12, 2026. The company officially reported this news to the public in an SEC 8-K filing on January 16, 2026.

• Immediate Action Required: Coeptis must submit a detailed plan to Nasdaq within 45 calendar days (from January 12, 2026) explaining how it will regain compliance.
• Company's Proposed Solution: Coeptis announced it will hold its annual shareholder meeting on January 30, 2026. The company believes successfully holding this meeting will bring it back into compliance with Nasdaq's rules.
• Nasdaq's Decision: If Nasdaq accepts Coeptis's plan, it may grant the company an extension of up to June 29, 2026, to fully regain compliance. This extension provides a window for the company to ensure all requirements are met.

Impact Assessment

This situation carries significant implications, particularly for a clinical-stage biotechnology company like Coeptis:

• Nasdaq Listing is Critical: Listing on Nasdaq provides credibility, visibility, and liquidity, facilitating stock trading for investors. For a biotech company, maintaining this listing is crucial for attracting capital to fund expensive research and development. Losing the listing (delisting) would severely damage its reputation and ability to raise funds.
• Investor Confidence: Failing to hold an annual meeting signals potential issues with the company's management, internal controls, or operational efficiency. It raises questions about transparency and accountability, which can erode trust and lead to a decline in stock price.
• Trading Difficulties & Market Perception: If a stock delists from Nasdaq, it often moves to less regulated, "over-the-counter" (OTC) markets. This makes the stock harder to trade, reduces its appeal to institutional investors, and generally decreases its market value and liquidity.
• Broader Risks: This compliance issue, while significant, also underscores the need to scrutinize a company's overall operational health, not just its scientific pipeline.

Who is affected?

• Existing Investors/Shareholders: Investors are directly affected. The stock price could drop, and if the company fails to resolve the issue, shares could become harder to trade and lose value if delisted.
• Potential Investors/Traders: This news adds significant risk, requiring thorough due diligence before investment. Potential investors may choose to await a clear resolution.
• The Company (Coeptis): Its reputation suffers, and it must dedicate resources to rectify this compliance issue. The ultimate risk is losing its Nasdaq listing, which could severely impact future funding and growth prospects.
• Employees: While not directly impacted daily, delisting or sustained loss of investor confidence could indirectly affect future funding, potentially impacting projects, job security, and overall company stability.

Financial Impact

The immediate financial impact of receiving the warning letter is not quantifiable as a direct charge or loss disclosed in the filing. However, the potential financial implications are significant:

• Stock Price Volatility: News of non-compliance can negatively affect investor confidence, potentially decreasing the stock price and increasing volatility.
• Access to Capital: Maintaining a Nasdaq listing is crucial for a public company to raise capital through equity offerings. A potential delisting could severely hinder future fundraising efforts, vital for a clinical-stage biotech company like Coeptis to fund its research and development.
• Increased Costs: The company will incur costs to address non-compliance, including legal and administrative expenses for preparing a compliance plan and holding the annual meeting.
• Reputational Damage: Reputational damage from non-compliance can have long-term financial consequences, making it harder to attract investors, partners, and talent.

Key Takeaways for Investors

• Watch the January 30th Meeting: The January 30, 2026, annual meeting is a crucial date. Investors should closely monitor news confirming the meeting occurred and Nasdaq's satisfaction with the outcome.
• Compliance is Not a Minor Detail: Maintaining a Nasdaq listing is vital for a public company's credibility, access to capital, and investor appeal. This is not merely a technicality; it reflects on management's operational discipline.
• Potential Volatility: Expect significant stock price reactions to compliance status news. Positive news could lead to a bounce, while negative developments could cause further drops.
• Governance Concerns: This situation raises questions about the company's internal controls and management oversight. Investors should consider if it indicates broader issues within leadership or operational structure.
• Broader Financial Health: Beyond this compliance issue, investors should review Coeptis's latest financial reports (10-K, 10-Q) to understand its cash position, burn rate, and ability to fund operations and clinical programs. These financial metrics are critical for any biotech company's long-term viability.
• Biotech-Specific Risks: Coeptis is a clinical-stage biotechnology company. Its long-term value fundamentally ties to the success of its drug pipeline and clinical trials. While serious, this governance issue should be considered alongside inherent drug development risks, including potential trial delays, failures, or regulatory hurdles.
• Do Your Homework: Biotech stocks can be very volatile. This delisting warning adds significant risk. Understand all implications and the company's overall risk profile before making trading decisions.